Top Markets
#1 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +33.37%
#2 Bitcoin Cash Bitcoin Cash +32.01%
#3 Tutorial Tutorial +31.14%
#4 Fabric Protocol Fabric Protocol +30.24%
#5 Arowana Arowana +27.39%
#6 Useless Coin Useless Coin +26.97%
#7 GALA GALA +26.88%
#8 Ethena Staked ENA Ethena Staked ENA +26.37%
#9 Audiera Audiera +26.21%
#10 Kamino Kamino +24.95%
Coin of the day
Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash
Settings
Language
ENGLISH
Currency
USD
Theme
Lytix Biopharma AS Lytix Biopharma AS

Lytix Biopharma AS

LYTIX
Rank in Stocks #24449
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology... Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Share Price
$0.78611575
Market Cap
$60.45M
Change (1 day)
0.00%
Change (1 year)
-12.06%
Country
NO
Trade Lytix Biopharma AS (LYTIX)

Category

Healthcare
Revenue for Lytix Biopharma AS (LYTIX)
Revenue in Aug 2026 TTM: 0
According to Lytix Biopharma AS latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Lytix Biopharma AS from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH